<?xml version="1.0" encoding="UTF-8"?><?xml-stylesheet href="https://www.accessdata.fda.gov/spl/stylesheet/spl.xsl" type="text/xsl"?>
<document xmlns="urn:hl7-org:v3" xmlns:xsi="http://www.w3.org/2001/XMLSchema-instance" xsi:schemaLocation="urn:hl7-org:v3 https://www.accessdata.fda.gov/spl/schema/spl.xsd">
   <id root="e6f889ff-c5ba-4324-b87c-ec3ac942be2f"/>
   <code code="34391-3" codeSystem="2.16.840.1.113883.6.1" displayName="Human Prescription Drug Label"/>
   <title>These highlights do not include all the information needed to use HYDROXYCHLOROQUINE SULFATE TABLETS safely and effectively. See full prescribing information for HYDROXYCHLOROQUINE SULFATE TABLETS.<br/>
      <br/> HYDROXYCHLOROQUINE SULFATE tablets, for oral use<br/> Initial U.S. Approval: 1955</title>
   <effectiveTime value="20250311"/>
   <setId root="e6f889ff-c5ba-4324-b87c-ec3ac942be2f"/>
   <versionNumber value="1"/>
   <author>
      <time/>
      <assignedEntity>
         <representedOrganization>
            <id root="1.3.6.1.4.1.519.1" extension="650082092"/>
            <name>Aurobindo Pharma Limited</name>
            <assignedEntity>
               <assignedOrganization>
                  <assignedEntity>
                     <assignedOrganization>
                        <id extension="650844777" root="1.3.6.1.4.1.519.1"/>
                        <name>APL HEALTHCARE LIMITED</name>
                     </assignedOrganization>
                     <performance>
                        <actDefinition>
                           <code code="C25391" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANALYSIS"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-889" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                     <performance>
                        <actDefinition>
                           <code code="C43360" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="MANUFACTURE"/>
                           <product>
                              <manufacturedProduct classCode="MANU">
                                 <manufacturedMaterialKind>
                                    <code code="59651-889" codeSystem="2.16.840.1.113883.6.69"/>
                                 </manufacturedMaterialKind>
                              </manufacturedProduct>
                           </product>
                        </actDefinition>
                     </performance>
                  </assignedEntity>
               </assignedOrganization>
            </assignedEntity>
         </representedOrganization>
      </assignedEntity>
   </author>
   <component>
      <structuredBody>
         <component>
            <section>
               <id root="bad0f80e-0da1-45f9-bab6-411958d46887"/>
               <code code="48780-1" codeSystem="2.16.840.1.113883.6.1" displayName="SPL PRODUCT DATA ELEMENTS SECTION"/>
               <effectiveTime value="20241217"/>
               <subject>
                  <manufacturedProduct>
                     <manufacturedProduct>
                        <code code="59651-889" codeSystem="2.16.840.1.113883.6.69"/>
                        <name>HYDROXYCHLOROQUINE SULFATE<suffix/>
                        </name>
                        <formCode code="C42931" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="TABLET, FILM COATED"/>
                        <asEntityWithGeneric>
                           <genericMedicine>
                              <name>HYDROXYCHLOROQUINE SULFATE</name>
                           </genericMedicine>
                        </asEntityWithGeneric>
                        <ingredient classCode="ACTIB">
                           <quantity>
                              <numerator value="200" unit="mg"/>
                              <denominator value="1" unit="1"/>
                           </quantity>
                           <ingredientSubstance>
                              <code code="8Q2869CNVH" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYDROXYCHLOROQUINE SULFATE</name>
                              <activeMoiety>
                                 <activeMoiety>
                                    <code code="4QWG6N8QKH" codeSystem="2.16.840.1.113883.4.9"/>
                                    <name>HYDROXYCHLOROQUINE</name>
                                 </activeMoiety>
                              </activeMoiety>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="3SY5LH9PMK" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>ANHYDROUS LACTOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="M28OL1HH48" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>CROSCARMELLOSE SODIUM</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0WZ8WG20P6" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (6 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="0VUT3PMY82" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (3 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="1IVH67816N" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>HYPROMELLOSE 2910 (50 MPA.S)</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="70097M6I30" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MAGNESIUM STEARATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="OP1R32D61U" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>MICROCRYSTALLINE CELLULOSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="VH2XOU12IE" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYDEXTROSE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="Q662QK8M3B" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POLYETHYLENE GLYCOL 8000</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="U725QWY32X" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>POVIDONE K30</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="368GB5141J" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>SODIUM LAURYL SULFATE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="15FIX9V2JP" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TITANIUM DIOXIDE</name>
                           </ingredientSubstance>
                        </ingredient>
                        <ingredient classCode="IACT">
                           <ingredientSubstance>
                              <code code="XHX3C3X673" codeSystem="2.16.840.1.113883.4.9"/>
                              <name>TRIACETIN</name>
                           </ingredientSubstance>
                        </ingredient>
                        <asContent>
                           <quantity>
                              <numerator value="100" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59651-889-01" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250307"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                        <asContent>
                           <quantity>
                              <numerator value="500" unit="1"/>
                              <denominator value="1"/>
                           </quantity>
                           <containerPackagedProduct>
                              <code code="59651-889-05" codeSystem="2.16.840.1.113883.6.69"/>
                              <formCode code="C43173" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="BOTTLE, PLASTIC"/>
                           </containerPackagedProduct>
                           <subjectOf>
                              <characteristic>
                                 <code code="SPLCMBPRDTP" codeSystem="2.16.840.1.113883.1.11.19255"/>
                                 <value code="C112160" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="Type 0: Not a Combination Product" xsi:type="CV"/>
                              </characteristic>
                           </subjectOf>
                           <subjectOf>
                              <marketingAct>
                                 <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                                 <statusCode code="active"/>
                                 <effectiveTime>
                                    <low value="20250307"/>
                                 </effectiveTime>
                              </marketingAct>
                           </subjectOf>
                        </asContent>
                     </manufacturedProduct>
                     <subjectOf>
                        <approval>
                           <id extension="ANDA040274" root="2.16.840.1.113883.3.150"/>
                           <code code="C73584" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ANDA"/>
                           <author>
                              <territorialAuthority>
                                 <territory>
                                    <code code="USA" codeSystem="2.16.840.1.113883.5.28"/>
                                 </territory>
                              </territorialAuthority>
                           </author>
                        </approval>
                     </subjectOf>
                     <subjectOf>
                        <marketingAct>
                           <code code="C53292" codeSystem="2.16.840.1.113883.3.26.1.1"/>
                           <statusCode code="active"/>
                           <effectiveTime>
                              <low value="20250307"/>
                           </effectiveTime>
                        </marketingAct>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLCOLOR" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48325" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="WHITE"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSHAPE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="CV" code="C48348" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ROUND">
                              <originalText>biconvex</originalText>
                           </value>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSIZE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="PQ" unit="mm" value="10"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLSCORE" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="INT" value="1"/>
                        </characteristic>
                     </subjectOf>
                     <subjectOf>
                        <characteristic classCode="OBS">
                           <code code="SPLIMPRINT" codeSystem="2.16.840.1.113883.1.11.19255"/>
                           <value xsi:type="ST">C</value>
                        </characteristic>
                     </subjectOf>
                     <consumedIn>
                        <substanceAdministration>
                           <routeCode code="C38288" codeSystem="2.16.840.1.113883.3.26.1.1" displayName="ORAL"/>
                        </substanceAdministration>
                     </consumedIn>
                  </manufacturedProduct>
               </subject>
            </section>
         </component>
         <component>
            <section ID="Section_1">
               <id root="926ad095-d1a1-410a-8179-1b4f842d1fd0"/>
               <code code="34067-9" codeSystem="2.16.840.1.113883.6.1" displayName="INDICATIONS &amp; USAGE SECTION"/>
               <title>1 INDICATIONS AND USAGE</title>
               <effectiveTime value="20241217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate tablets are an antimalarial and antirheumatic indicated for the: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Treatment of uncomplicated malaria due to <content styleCode="italics">Plasmodium falciparum, Plasmodium malariae, Plasmodium ovale, and Plasmodium vivax </content>in adult and pediatric patients. (<linkHtml href="#Section_1.1">1.1</linkHtml>) </item>
                           <item>Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported in adult and pediatric patients. (<linkHtml href="#Section_1.1">1.1</linkHtml>) </item>
                           <item>Treatment of rheumatoid arthritis in adults. (<linkHtml href="#Section_1.2">1.2</linkHtml>) </item>
                           <item>Treatment of systemic lupus erythematosus in adults. (<linkHtml href="#Section_1.3">1.3</linkHtml>) </item>
                           <item>Treatment of chronic discoid lupus erythematosus in adults. (<linkHtml href="#Section_1.4">1.4</linkHtml>) </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use (<linkHtml href="#Section_1.1">1.1</linkHtml>)</content>: </paragraph>
                        <paragraph>Hydroxychloroquine sulfate tablets are <content styleCode="bold">not </content>recommended for the: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Treatment of complicated malaria.</item>
                           <item>Treatment of chloroquine or hydroxychloroquine-resistant strains of <content styleCode="italics">Plasmodium </content>species.</item>
                           <item>Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the <content styleCode="italics">Plasmodium </content>species has not been identified.</item>
                           <item>Prophylaxis of malaria in geographic areas where chloroquine resistance occurs.</item>
                           <item>Prevention of relapses of <content styleCode="italics">P. vivax </content>or <content styleCode="italics">P. ovale </content>because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of <content styleCode="italics">P. vivax </content>and <content styleCode="italics">P. ovale </content>infections, concomitant therapy with an 8-aminoquinoline drug is necessary. </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_1.1">
                     <id root="6e098c9f-0d17-4ed8-a753-f63bbca1575c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.1 Malaria</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate tablets are indicated in adult and pediatric patients for the: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Treatment of uncomplicated malaria due to <content styleCode="italics">Plasmodium falciparum, Plasmodium malariae, Plasmodium vivax, </content>and <content styleCode="italics">Plasmodium ovale. </content>
                           </item>
                           <item>Prophylaxis of malaria in geographic areas where chloroquine resistance is not reported.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Limitations of Use:</content>
                           <br/>
                           <br/> Hydroxychloroquine sulfate tablets are <content styleCode="bold">not </content>recommended for: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Treatment of complicated malaria.</item>
                           <item>Treatment of malaria by chloroquine or hydroxychloroquine-resistant strains of <content styleCode="italics">Plasmodium </content>species <content styleCode="italics">[see <linkHtml href="#Section_12.4">Microbiology (12.4)</linkHtml>]</content>.</item>
                           <item>Treatment of malaria acquired in geographic areas where chloroquine resistance occurs or when the <content styleCode="italics">Plasmodium </content>species has not been identified.</item>
                           <item>Prophylaxis of malaria in geographic areas where chloroquine resistance occurs.</item>
                           <item>Prevention of relapses of <content styleCode="italics">P. vivax </content>or <content styleCode="italics">P. ovale </content>because it is not active against the hypnozoite liver stage forms of these parasites. For radical cure of <content styleCode="italics">P. vivax </content>and <content styleCode="italics">P. ovale </content>infections, concomitant therapy with an 8-aminoquinoline drug is necessary <content styleCode="italics">[see <linkHtml href="#Section_12.4">Microbiology (12.4)</linkHtml>]</content>.</item>
                        </list>
                        <paragraph>For the most current information about drug resistance, refer to the latest recommendations from the Center for Disease Control and Prevention <sup>1</sup>.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.2">
                     <id root="e0b98280-e846-44a5-9c5c-14964d52bab8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.2 Rheumatoid Arthritis</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate tablets are indicated for the treatment of acute and chronic rheumatoid arthritis in adults. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.3">
                     <id root="8daa5d3c-d0c9-496f-b890-9baeeab7b50a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.3 Systemic Lupus Erythematosus</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate tablets are indicated for the treatment of systemic lupus erythematosus in adults. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_1.4">
                     <id root="8558670b-6e88-4fcf-b216-95c048b18100"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>1.4 Chronic Discoid Lupus Erythematosus</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate tablets are indicated for the treatment of chronic discoid lupus erythematosus in adults. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_2">
               <id root="37908376-b3a3-4781-9a45-4564f8e3d5d7"/>
               <code code="34068-7" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE &amp; ADMINISTRATION SECTION"/>
               <title>2 DOSAGE AND ADMINISTRATION</title>
               <effectiveTime value="20241217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Malaria in Adult and Pediatric Patients </content>(<linkHtml href="#Section_2.2">2.2</linkHtml>): </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Prophylaxis: Begin weekly doses 2 weeks prior to travel to the endemic area, continue weekly doses while in the endemic area, and continue the weekly doses for 4 weeks after leaving the endemic area: </item>
                        </list>
                        <paragraph>        - Adults: 400 mg once a week</paragraph>
                        <paragraph>        - Pediatric patients ≥ 31 kg: 6.5 mg/kg up to 400 mg, once a week<br/>  </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Treatment of Uncomplicated Malaria: See Full Prescribing Information (FPI) for complete dosing information.</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Rheumatoid Arthritis in Adults </content>(<linkHtml href="#Section_2.3">2.3</linkHtml>): </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Initial dosage: 400 mg to 600 mg daily </item>
                           <item>Chronic dosage: 200 mg once daily or 400 mg once daily (or in two divided doses) </item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Systemic Lupus Erythematosus in Adults </content>(<linkHtml href="#Section_2.4">2.4</linkHtml>): </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>200 mg once daily or 400 mg once daily (or in two divided doses)</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Chronic Discoid Lupus Erythematosus in Adults </content>(<linkHtml href="#Section_2.5">2.5</linkHtml>): </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>200 mg once daily or 400 mg once daily (or in two divided doses) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_2.1">
                     <id root="3b563831-b8d6-483a-b315-6d56f44c530e"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.1 Important Administration Instructions</title>
                     <text>
                        <paragraph>Administer hydroxychloroquine sulfate tablets orally with food or milk. Do not crush or divide the tablets.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.2">
                     <id root="12530974-aa70-4139-879c-b697025dfa22"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.2 Dosage for Malaria in Adult and Pediatric Patients</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate tablets are not recommended in pediatric patients less than 31 kg because the lowest available strength (200 mg) exceeds the recommended dose for these patients and it cannot be divided.<br/>
                           <br/>
                           <content styleCode="underline">Prophylaxis</content>
                           <br/>
                           <br/> Treatment must start 2 weeks before travel to an endemic area. Advise the patient to take the prophylaxis dosage once a week, staring 2 weeks prior to travel to the endemic area, on the same day every week, continuing the same weekly dose while in the endemic area, and for 4 weeks after leaving the endemic area. The recommended prophylaxis dosage is:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Adult patients: 400 mg once a week </item>
                           <item>Pediatric patients ≥ 31 kg: 6.5 mg/kg actual body weight (up to 400 mg) once a week</item>
                        </list>
                        <paragraph>
                           <content styleCode="underline">Treatment of Uncomplicated Malaria</content>
                           <br/>
                           <br/> The dosages for the treatment of uncomplicated malaria are: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Adult patients: Administer 800 mg initially; subsequently administer 400 mg at 6 hours, 24 hours, and 48 hours after the initial dose (total dosage = 2000 mg). </item>
                           <item>Pediatric patients ≥ 31 kg: Administer 13 mg/kg (up to 800 mg) initially; subsequently administer 6.5 mg/kg (up to 400 mg) at 6 hours, 24 hours, and 48 hours after the initial dose (total dosage = 31 mg/kg - up to 2000 mg). </item>
                        </list>
                        <paragraph>For radical cure of <content styleCode="italics">P. vivax and P. ovale </content>infections, concomitant therapy with an 8-aminoquinoline drug is necessary <content styleCode="italics">[see <linkHtml href="#Section_12.4">Microbiology (12.4)</linkHtml>]</content>.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.3">
                     <id root="08b85155-6623-400e-9152-bd13b0079816"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.3 Dosage for Rheumatoid Arthritis in Adults</title>
                     <text>
                        <paragraph>The recommended dosage is: </paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Initial dosage: 400 mg to 600 mg daily as a single daily dose or two divided doses. The action of hydroxychloroquine is cumulative and may require weeks to months for maximum therapeutic effect. Daily doses exceeding 5 mg/kg (actual weight) of hydroxychloroquine sulfate increase the incidence of retinopathy <content styleCode="italics">[see <linkHtml href="#Section_5.2">Warnings and Precautions (5.2)</linkHtml>]</content>.<content styleCode="italics"/>
                           </item>
                           <item>Chronic dosage: 200 mg once daily to 400 mg daily, as a single dose or two divided doses. </item>
                        </list>
                        <paragraph>Corticosteroids, salicylates, and other antirheumatic agents may be used concomitantly with hydroxychloroquine sulfate tablets. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.4">
                     <id root="79373fed-9c22-41f3-b34d-500657f8d41f"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.4 Dosage for Systemic Lupus Erythematosus in Adults</title>
                     <text>
                        <paragraph>The recommended dosage is 200 mg given once daily, or 400 mg given once daily or in two divided doses. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_2.5">
                     <id root="23cbed6d-c8eb-405d-a897-4e92b2f6ff8c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>2.5 Dosage for Chronic Discoid Lupus Erythematosus in Adults</title>
                     <text>
                        <paragraph>The recommended dosage is 200 mg given once daily, or 400 mg given once daily or in two divided doses. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_3">
               <id root="d6e6ee5b-ff2a-4096-a9c3-905851a60111"/>
               <code code="43678-2" codeSystem="2.16.840.1.113883.6.1" displayName="DOSAGE FORMS &amp; STRENGTHS SECTION"/>
               <title>3 DOSAGE FORMS AND STRENGTHS</title>
               <text>
                  <paragraph>Hydroxychloroquine sulfate tablets, USP are available containing 200 mg of hydroxychloroquine sulfate, USP equivalent to 155 mg of base. </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>The 200 mg tablets are a white, film-coated, round, biconvex, beveled edge tablet debossed with “C” on one side of the tablet and plain on the other side. </item>
                  </list>
               </text>
               <effectiveTime value="20241217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>Tablets: 200 mg of hydroxychloroquine sulfate (<linkHtml href="#Section_3">3</linkHtml>)  </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_4">
               <id root="92fa5f36-d974-49b6-a618-cbf16abb420f"/>
               <code code="34070-3" codeSystem="2.16.840.1.113883.6.1" displayName="CONTRAINDICATIONS SECTION"/>
               <title>4 CONTRAINDICATIONS</title>
               <text>
                  <paragraph>Hydroxychloroquine sulfate is contraindicated in patients with known hypersensitivity to 4-aminoquinoline compounds.</paragraph>
               </text>
               <effectiveTime value="20241217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Patients with hypersensitivity to 4-aminoquinoline compounds (<linkHtml href="#Section_4">4</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_5">
               <id root="7c182f7e-4bcd-4c32-a01e-b9c5b92f65a6"/>
               <code code="43685-7" codeSystem="2.16.840.1.113883.6.1" displayName="WARNINGS AND PRECAUTIONS SECTION"/>
               <title>5 WARNINGS AND PRECAUTIONS</title>
               <effectiveTime value="20241217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>
                              <content styleCode="underline">Cardiomyopathy and Ventricular Arrhythmias</content>: Fatal or life-threatening cardiomyopathy and ventricular arrhythmias were reported. (<linkHtml href="#Section_5.1">5.1</linkHtml>) </item>
                           <item>
                              <content styleCode="underline">Retinal Toxicity</content>: Irreversible retinal damage is related to cumulative dosage and treatment duration. Baseline retinal exam and exams during treatment are recommended. (<linkHtml href="#Section_5.2">5.2</linkHtml>) </item>
                           <item>
                              <content styleCode="underline">Serious Skin Reactions</content>: Stevens Johnson syndrome, toxic epidermal necrolysis, drug reaction with eosinophilia and systemic symptoms, acute generalized exanthematous pustulosis have been reported. (<linkHtml href="#Section_5.3">5.3</linkHtml>) </item>
                           <item>
                              <content styleCode="underline">Worsening of Psoriasis</content>: Avoid in patients with psoriasis. (<linkHtml href="#Section_5.4">5.4</linkHtml>) </item>
                           <item>
                              <content styleCode="underline">Risks Associated with Use in Porphyria</content>: Avoid in patients with porphyria. Hepatotoxicity was reported in patients with porphyria cutanea tarda. (<linkHtml href="#Section_5.5">5.5</linkHtml>)</item>
                           <item>
                              <content styleCode="underline">Hematologic Toxicity</content>: Discontinue if myelosuppression occurs. (<linkHtml href="#Section_5.6">5.6</linkHtml>) </item>
                           <item>
                              <content styleCode="underline">Renal Toxicity</content>: Consider phospholipidosis as a possible cause of renal injury in patients with underlying connective tissue disorders. Discontinue hydroxychloroquine sulfate if renal toxicity is suspected or demonstrated by tissue biopsy in any organ system. (<linkHtml href="#Section_5.1">5.1</linkHtml>, <linkHtml href="#Section_5.8">5.8</linkHtml>, <linkHtml href="#Section_5.11">5.11</linkHtml>)</item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_5.1">
                     <id root="a2094319-8cc3-4b3a-9d3f-581053ebb9fe"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.1 Cardiomyopathy and Ventricular Arrhythmias</title>
                     <text>
                        <paragraph>Fatal and life-threatening cases of cardiotoxicity, including cardiomyopathy, have been reported in patients treated with hydroxychloroquine sulfate. Signs and symptoms of cardiac compromise have occurred during acute and chronic hydroxychloroquine sulfate treatment. In multiple cases, endomyocardial biopsy showed association of the cardiomyopathy with phospholipidosis in the absence of inflammation, infiltration, or necrosis. Drug-induced phospholipidosis may occur in other organ systems [see <content styleCode="italics">
                              <linkHtml href="#Section_5.8">Warnings and Precautions (5.8</linkHtml>, <linkHtml href="#Section_5.11">5.11</linkHtml>)</content>].</paragraph>
                        <br/>
                        <paragraph>Patients may present with ventricular hypertrophy, pulmonary hypertension and conduction disorders including sick sinus syndrome. ECG findings include atrioventricular, right or left bundle branch block. </paragraph>
                        <br/>
                        <paragraph>Hydroxychloroquine sulfate has a potential to prolong the QT interval. Ventricular arrhythmias (including torsades de pointes) have been reported in hydroxychloroquine sulfate-treated patients. The magnitude of QT prolongation may increase with increasing concentrations of the drug. Therefore, the recommended dose should not be exceeded <content styleCode="italics">[see <linkHtml href="#Section_6">Adverse Reactions (6)</linkHtml>
                           </content>, <content styleCode="italics">
                              <linkHtml href="#Section_10">Overdosage (10)</linkHtml>]</content>. Avoid hydroxychloroquine sulfate administration in patients with congenital or documented acquired QT prolongation and/or known risk factors for prolongation of the QT interval such as:</paragraph>
                        <list listType="unordered" styleCode="disc">
                           <item>Cardiac disease, e.g., heart failure, myocardial infarction. </item>
                           <item>Proarrhythmic conditions, e.g., bradycardia (&lt; 50 bpm). </item>
                           <item>History of ventricular dysrhythmias. </item>
                           <item>Uncorrected hypokalemia and/or hypomagnesemia. </item>
                           <item>Concomitant administration with QT interval prolonging agents as this may lead to an increased risk for ventricular arrhythmias <content styleCode="italics">[see <linkHtml href="#Section_7.1">Drug Interactions (7.1)</linkHtml>].</content>
                           </item>
                        </list>
                        <paragraph>Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval. Monitor cardiac function as clinically indicated during hydroxychloroquine sulfate therapy. Correct electrolyte imbalances prior to use. Discontinue hydroxychloroquine sulfate if cardiotoxicity is suspected or demonstrated by tissue biopsy.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.2">
                     <id root="934cccc3-f1a9-4170-8354-341d1f870a85"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.2 Retinal Toxicity</title>
                     <text>
                        <paragraph>Irreversible retinal damage was observed in some patients treated with hydroxychloroquine sulfate and it is related to cumulative dosage and treatment duration. In patients of Asian descent, retinal toxicity may first be noticed outside the macula. </paragraph>
                        <br/>
                        <paragraph>Risk factors for retinal damage include daily hydroxychloroquine sulfate dosages ≥5 mg/kg of actual body weight, durations of use greater than five years, renal impairment, use of concomitant drug products such as tamoxifen citrate, and concurrent macular disease. </paragraph>
                        <br/>
                        <paragraph>Within the first year of starting hydroxychloroquine sulfate, a baseline ocular examination is recommended including best corrected distance visual acuity (BCVA), an automated threshold visual field (VF) of the central 10 degrees (with retesting if an abnormality is noted), and spectral domain ocular coherence tomography (SD-OCT). For patients at higher risk of retinal damage, monitoring should include annual examinations which include BCVA, VF and SD-OCT. For patients without significant risk factors, annual retinal exams can usually be deferred until five years of treatment. In patients of Asian descent, it is recommended that visual field testing be performed in the central 24 degrees instead of the central 10 degrees.</paragraph>
                        <br/>
                        <paragraph>If ocular toxicity is suspected, discontinue hydroxychloroquine sulfate and monitor the patient closely given that retinal changes and visual disturbances may progress even after cessation of therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.3">
                     <id root="3c29a9d9-a59c-424f-ad6e-f5f6b22d9978"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.3 Serious Skin Reactions</title>
                     <text>
                        <paragraph>Serious adverse reactions have been reported with the use of hydroxychloroquine sulfate including Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN), drug reaction with eosinophilia and systemic symptoms (DRESS syndrome), acute generalized exanthematous pustulosis (AGEP). Monitor for serious skin reactions, especially in patients receiving a drug that may also induce dermatitis. Advise patients to seek medical attention promptly if they experience signs and symptoms of serious skin reactions such as blisters on the skin, eyes, lips or in the mouth, itching or burning, with or without fever <content styleCode="italics">[see <linkHtml href="#Section_5.4">Warnings and Precautions (5.4</linkHtml>, <linkHtml href="#Section_5.11">5.5</linkHtml>), <linkHtml href="#Section_6">Adverse Reactions (6)</linkHtml>]</content>. Discontinue hydroxychloroquine sulfate if these severe reactions occur.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.4">
                     <id root="9876fff5-86bb-4d51-a46f-d0ff0cd04010"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.4 Worsening of Psoriasis</title>
                     <text>
                        <paragraph>Administration of hydroxychloroquine sulfate to patients with psoriasis may precipitate a severe flare-up of psoriasis. Avoid hydroxychloroquine sulfate in patients with psoriasis, unless the benefit to the patient outweighs the possible risk. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.5">
                     <id root="be22ca37-9fab-459d-a1f9-6eee3945f6b8"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.5 Risks Associated with Use in Porphyria</title>
                     <text>
                        <br/>
                        <paragraph>Administration of hydroxychloroquine sulfate to patients with porphyria may exacerbate porphyria. Avoid hydroxychloroquine sulfate in patients with porphyria.</paragraph>
                        <br/>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Hepatotoxicity Associated with Porphyria Cutanea Tarda </content>
                        </paragraph>
                        <br/>
                        <paragraph>Cases of hepatotoxicity have been reported when hydroxychloroquine was used in patients with porphyria cutanea tarda (PCT). Patients received dosages ranging from 200 mg twice weekly to 400 mg daily. Most of the PCT-related cases presented with marked elevations in transaminases (&gt;20 times upper limit of the reference range) within days to a month of hydroxychloroquine initiation. In some cases, PCT was diagnosed only after the occurrence of treatment-induced liver injury, when hydroxychloroquine was prescribed for an approved indication. Some of the cases were associated with other risk factors for hepatic injury (e.g., alcohol use, concomitant hepatotoxic medications). </paragraph>
                        <br/>
                        <paragraph>Measure liver tests promptly in patients who report symptoms that may indicate liver injury, such as fatigue, rash, nausea, dark urine, or jaundice. In this clinical context, if the patient is found to have abnormal serum liver tests (e.g., ALT level greater than three times the upper limit of the reference range, total bilirubin greater than two times the upper limit of the reference range), interrupt treatment with hydroxychloroquine sulfate, and investigate further to establish the probable cause.</paragraph>
                        <br/>
                        <paragraph>The safety and effectiveness of hydroxychloroquine sulfate for the treatment of PCT have not been established and hydroxychloroquine sulfate is not approved for this use.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.6">
                     <id root="51ca203e-9c52-479d-b547-379a5dc13012"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.6 Hematologic Toxicity</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate may cause myelosuppression including aplastic anemia, agranulocytosis, leukopenia, or thrombocytopenia. Monitor blood cell counts periodically in patients on prolonged hydroxychloroquine sulfate therapy. If the patient develops myelosuppression which cannot be attributable to the disease, discontinue the drug. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.7">
                     <id root="c7be46eb-a040-456a-be33-0e6dcacef5ee"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.7 Hemolytic Anemia Associated with G6PD Deficiency</title>
                     <text>
                        <paragraph>Hemolysis has been reported in patients with glucose-6-phosphate dehydrogenase (G6PD) deficiency. Monitor for hemolytic anemia as this can occur, particularly in association with other drugs that cause hemolysis.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.8">
                     <id root="4b9e8db8-6bc5-4b39-8c76-6abc6bca0c79"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.8 Skeletal Muscle Myopathy or Neuropathy</title>
                     <text>
                        <paragraph>Skeletal muscle myopathy or neuropathy leading to progressive weakness and atrophy of proximal muscle groups, depressed tendon reflexes, and abnormal nerve conduction, have been reported. Muscle and nerve biopsies have shown associated phospholipidosis. Drug-induced phospholipidosis may occur in other organ systems <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#Section_5.1">Warnings and Precautions (5.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#Section_5.11">5.11)</linkHtml>
                           </content>
                           <content styleCode="italics">].</content>
                        </paragraph>
                        <br/>
                        <paragraph>Assess muscle strength and deep tendon reflexes periodically in patients on long-term therapy with hydroxychloroquine sulfate. Discontinue hydroxychloroquine sulfate if muscle or nerve toxicity is suspected or demonstrated by tissue biopsy.<content styleCode="bold"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.9">
                     <id root="61402626-c497-4a32-a7eb-bd1818e74087"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.9 Neuropsychiatric Reactions Including Suicidality</title>
                     <text>
                        <br/>
                        <paragraph>Suicidal behavior, suicidal ideation, and other neuropsychiatric adverse reactions have been reported in patients treated with hydroxychloroquine sulfate <content styleCode="italics">[see <linkHtml href="#Section_6">Adverse Reactions (6)</linkHtml>]</content>. Neuropsychiatric adverse reactions typically occurred within the first month after the start of treatment with hydroxychloroquine and have been reported in patients with and without a prior history of psychiatric disorders. <br/>
                           <br/> The risks and benefits of continued treatment with hydroxychloroquine sulfate should be assessed for patients who develop these symptoms. Given the long half-life of the drug, some patients may require several weeks off drug for symptoms to partially or fully abate. <br/>
                           <br/> Advise patients to contact their healthcare provider promptly if they experience new or worsening neuropsychiatric symptoms such as depression, suicidal thoughts or behavior, or mood changes.</paragraph>
                        <br/>
                        <br/>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.10">
                     <id root="44e5e9a9-60ec-4878-8ba4-18677eacb9b0"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.10 Hypoglycemia</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate can cause severe and potentially life-threatening hypoglycemia, in the presence or absence of antidiabetic agents <content styleCode="italics">[see <linkHtml href="#Section_7">Drug Interactions (7)</linkHtml>]</content>. Measure blood glucose in patients presenting with clinical symptoms suggestive of hypoglycemia and as adjust the antidiabetic treatment as necessary. Warn hydroxychloroquine sulfate-treated patients about the risk of hypoglycemia and educate them on the signs and symptoms of hypoglycemia; diabetic patients should monitor their blood sugar levels. Advise patients to seek medical attention if they develop any signs and symptoms of hypoglycemia.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_5.11">
                     <id root="71a958fe-23cc-4ef8-8cd9-1f2653f3b89a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>5.11 Renal Toxicity</title>
                     <text>
                        <paragraph>Proteinuria with or without moderate reduction in glomerular filtration rate have been reported with the use of hydroxychloroquine sulfate.</paragraph>
                        <br/>
                        <paragraph>Renal biopsy showed phospholipidosis without immune deposits, inflammation, and/or increased cellularity. Physicians should consider phospholipidosis as a possible cause of renal injury in patients with underlying connective tissue disorders who are receiving hydroxychloroquine sulfate. Drug-induced phospholipidosis may occur in other organ systems <content styleCode="italics">[see </content>
                           <content styleCode="italics">
                              <linkHtml href="#Section_5.1">Warnings and Precautions (5.1</linkHtml>
                           </content>
                           <content styleCode="italics">, </content>
                           <content styleCode="italics">
                              <linkHtml href="#Section_5.8">5.8</linkHtml>
                           </content>
                           <content styleCode="italics">)</content>
                           <content styleCode="italics">]</content>. Discontinue hydroxychloroquine sulfate if renal toxicity is suspected or demonstrated by tissue biopsy.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_6">
               <id root="9f24ff3f-fa3c-47ac-a115-4db932c416d6"/>
               <code code="34084-4" codeSystem="2.16.840.1.113883.6.1" displayName="ADVERSE REACTIONS SECTION"/>
               <title>6 ADVERSE REACTIONS</title>
               <text>
                  <paragraph>The following adverse reactions are described in greater detail in other sections: </paragraph>
                  <br/>
                  <list listType="unordered" styleCode="disc">
                     <item>Cardiomyopathy and Ventricular Arrhythmias <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1)</linkHtml>] </content>
                     </item>
                     <item>Retinal Toxicity <content styleCode="italics">[see <linkHtml href="#Section_5.2">Warnings and Precautions (5.2)</linkHtml>] </content>
                     </item>
                     <item>Serious Skin Reactions <content styleCode="italics">[see <linkHtml href="#Section_5.3">Warnings and Precautions (5.3)</linkHtml>] </content>
                     </item>
                     <item>Worsening of Psoriasis <content styleCode="italics">[see <linkHtml href="#Section_5.4">Warnings and Precautions (5.4)</linkHtml>] </content>
                     </item>
                     <item>Risks Associated with Use in Porphyria <content styleCode="italics">[see <linkHtml href="#Section_5.5">Warnings and Precautions (5.5)</linkHtml>]</content>
                     </item>
                     <item>Hematologic Toxicity <content styleCode="italics">[see <linkHtml href="#Section_5.6">Warnings and Precautions (5.6)</linkHtml>] </content>
                     </item>
                     <item>Hemolytic Anemia Associated with G6PD <content styleCode="italics">[see <linkHtml href="#Section_5.7">Warnings and Precautions (5.7)</linkHtml>] </content>
                     </item>
                     <item>Skeletal Muscle Myopathy or Neuropathy <content styleCode="italics">[see <linkHtml href="#Section_5.8">Warnings and Precautions (5.8)</linkHtml>] </content>
                     </item>
                     <item>Neuropsychiatric Reactions Including Suicidality <content styleCode="italics">[see <linkHtml href="#Section_5.9">Warnings and Precautions (5.9)</linkHtml>] </content>
                     </item>
                     <item>Hypoglycemia <content styleCode="italics">[see <linkHtml href="#Section_5.10">Warnings and Precautions (5.10)</linkHtml>] </content>
                     </item>
                     <item>Renal Toxicity <content styleCode="italics">[see <linkHtml href="#Section_5.11">Warnings and Precautions (5.11)</linkHtml>] </content>
                     </item>
                  </list>
                  <paragraph>  </paragraph>
                  <paragraph>The following adverse reactions have been identified during post-approval use of 4-aminoquinoline drugs, including hydroxychloroquine sulfate. Because these reactions are reported voluntarily from a population of uncertain size, it is not always possible to reliably estimate their frequency or establish a causal relationship to drug exposure:</paragraph>
                  <br/>
                  <paragraph>‒     <content styleCode="italics">Blood and lymphatic system disorders:</content> Bone marrow depression, anemia, aplastic anemia, agranulocytosis, leukopenia, thrombocytopenia </paragraph>
                  <paragraph>‒     <content styleCode="italics">Cardiac disorders: </content>Cardiomyopathy, cardiac failure, QT-interval prolongation, ventricular tachycardia, torsades de pointes, atrioventricular block, bundle branch block, sick sinus syndrome, pulmonary hypertension </paragraph>
                  <paragraph>‒     <content styleCode="italics">Ear and labyrinth disorders:</content> Vertigo, tinnitus, nystagmus, sensorineural hearing loss</paragraph>
                  <paragraph>‒     <content styleCode="italics">Eye disorders: </content>Retinopathy, retinal pigmentation changes (typically bull’s eye appearance), visual field defects (paracentral scotomas), macular degeneration, corneal edema, corneal opacities, decreased dark adaptation</paragraph>
                  <paragraph>‒     <content styleCode="italics">Gastrointestinal disorders: </content>Nausea, vomiting, diarrhea, abdominal pain</paragraph>
                  <paragraph>‒     <content styleCode="italics">General disorders: </content>Fatigue</paragraph>
                  <paragraph>‒     <content styleCode="italics">Hepatobiliary disorders: </content>Abnormal liver function tests, fulminant hepatic failure</paragraph>
                  <paragraph>‒     <content styleCode="italics">Immune system disorders:</content> Urticaria, angioedema, bronchospasm</paragraph>
                  <paragraph>‒     <content styleCode="italics">Metabolism and nutrition disorders:</content> Anorexia, hypoglycemia, weight loss</paragraph>
                  <paragraph>‒     <content styleCode="italics">Musculoskeletal and connective tissue disorders: </content>Proximal myopathy, depressed tendon reflexes, abnormal nerve conduction</paragraph>
                  <paragraph>‒     <content styleCode="italics">Nervous system disorders: </content>Ataxia, dizziness, headache, seizure, extrapyramidal disorders (dystonia, dyskinesia, tremor)</paragraph>
                  <paragraph>‒     <content styleCode="italics">Neuropsychiatric disorders: </content>Affect/emotional lability, irritability, nervousness, psychosis, suicidal ideation, suicidal behavior, depression, hallucinations, anxiety, agitation, confusion, delusions, paranoia, mania and sleep disorders (insomnia, night terrors, nightmares) <br/>
                     <br/>‒     <content styleCode="italics">Skin and subcutaneous tissue disorders: </content>Alopecia, hair color changes, rash, pruritus, photosensitivity, psoriasis exacerbation, hyperpigmentation, exfoliative dermatitis, erythema multiforme, acute generalized exanthematous pustulosis, Drug Rash with Eosinophilia and  Systemic Symptoms (DRESS syndrome), Stevens-Johnson syndrome (SJS), toxic epidermal necrolysis (TEN)</paragraph>
               </text>
               <effectiveTime value="20241217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <paragraph>The most common adverse reactions reported are: nausea, vomiting, diarrhea, and abdominal pain. (<linkHtml href="#Section_6">6</linkHtml>) <br/>
                           <content styleCode="bold">
                              <br/>
                              <content styleCode="bold">To report SUSPECTED ADVERSE REACTIONS, contact Aurobindo Pharma USA, Inc. at 1-866-850-2876 or FDA at 1-800-FDA-1088 or </content>
                              <content styleCode="bold">
                                 <content styleCode="italics">www.fda.gov/medwatch</content>
                              </content>
                              <content styleCode="bold">
                                 <content styleCode="italics">.</content>
                              </content>
                           </content>
                        </paragraph>
                     </text>
                  </highlight>
               </excerpt>
            </section>
         </component>
         <component>
            <section ID="Section_7">
               <id root="58e2639e-6f59-40d9-a991-071aec6508eb"/>
               <code code="34073-7" codeSystem="2.16.840.1.113883.6.1" displayName="DRUG INTERACTIONS SECTION"/>
               <title>7 DRUG INTERACTIONS</title>
               <effectiveTime value="20241217"/>
               <excerpt>
                  <highlight>
                     <text>
                        <list listType="unordered" styleCode="disc">
                           <item>Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs. (<linkHtml href="#Section_7.1">7.1</linkHtml>) </item>
                           <item>See FPI for more important drug interactions. (<linkHtml href="#Section_7">7</linkHtml>) </item>
                        </list>
                     </text>
                  </highlight>
               </excerpt>
               <component>
                  <section ID="Section_7.1">
                     <id root="aafc6f1c-1cb8-47b5-8952-ffa1f3109160"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.1 Drugs Prolonging QT Interval and Other Arrhythmogenic Drugs</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate prolongs the QT interval. There may be an increased risk of inducing ventricular arrhythmias if hydroxychloroquine sulfate is used concomitantly with other arrhythmogenic drugs. Therefore, hydroxychloroquine sulfate is not recommended in patients taking other drugs that have the potential to prolong the QT interval or are arrhythmogenic <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1)</linkHtml>]</content>.<content styleCode="italics"/>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.2">
                     <id root="30522a63-21b6-4a60-841f-44fd28a4342c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.2 Insulin or Other Antidiabetic Drugs</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate may enhance the effects of insulin and antidiabetic drugs, and consequently increase the hypoglycemic risk. Therefore, a decrease in dosage of insulin and other antidiabetic drugs may be necessary <content styleCode="italics">[see <linkHtml href="#Section_5.10">Warnings and Precautions (5.10)</linkHtml>]</content>. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.3">
                     <id root="1468af70-52ce-4b5a-847e-b41f2784f1a9"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.3 Drugs that Lower the Seizure Threshold</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate can lower the seizure threshold. Co-administration of hydroxychloroquine sulfate with other antimalarials known to lower the seizure threshold (e.g., mefloquine) may increase the risk of seizures.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.4">
                     <id root="34ebbd52-f711-41ef-b02f-2ab036f776cc"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.4 Antiepileptics</title>
                     <text>
                        <paragraph>The activity of antiepileptic drugs might be impaired if co-administered with hydroxychloroquine sulfate. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.5">
                     <id root="b02d47d6-81c9-424b-a935-b6bd9c108724"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.5 Methotrexate</title>
                     <text>
                        <paragraph>Concomitant use of hydroxychloroquine sulfate and methotrexate may increase the incidence of adverse reactions. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.6">
                     <id root="f7336e05-10fd-4f8f-bbb7-1db813e0f67c"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.6 Cyclosporine</title>
                     <text>
                        <paragraph>An increased plasma cyclosporin level was reported when cyclosporin and hydroxychloroquine sulfate were co-administered. Monitor serum cyclosporine levels closely in patients receiving combined therapy. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.7">
                     <id root="4ca7a686-3da5-454b-b215-373306bc16d1"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.7 Digoxin</title>
                     <text>
                        <paragraph>Concomitant hydroxychloroquine sulfate and digoxin therapy may result in increased serum digoxin levels. Monitor serum digoxin levels closely in patients receiving combined therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.8">
                     <id root="f0b549bc-5020-4e6c-8653-e2235712d9af"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.8 Cimetidine</title>
                     <text>
                        <paragraph>Concomitant use of cimetidine resulted in a 2-fold increase of exposure of chloroquine, which is structurally related to hydroxychloroquine. Interaction of cimetidine with hydroxychloroquine cannot be ruled out. Avoid concomitant use of cimetidine. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.9">
                     <id root="82c8e503-bd45-407e-89d1-63aee7782a03"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.9 Rifampicin</title>
                     <text>
                        <paragraph>Lack of efficacy of hydroxychloroquine was reported when rifampicin was concomitantly administered. Avoid concomitant use of rifampicin. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.10">
                     <id root="5e7f71f8-9868-4f0e-8c03-5923eb30c4f4"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.10 Praziquantel</title>
                     <text>
                        <paragraph>Chloroquine has been reported to reduce the bioavailability of praziquantel. Interaction of praziquantel with hydroxychloroquine cannot be ruled out. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.11">
                     <id root="dc3be4e4-de61-4db4-b2bb-5f06fec99201"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.11 Antacids and kaolin</title>
                     <text>
                        <paragraph>Antacids and kaolin can reduce absorption of chloroquine; an interval of at least 4 hours between intake of these agents and chloroquine should be observed. Interaction of antacids and kaolin with hydroxychloroquine cannot be ruled out. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_7.12">
                     <id root="1e83bff3-5bc0-455f-87f3-77c2a262270d"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>7.12 Ampicillin</title>
                     <text>
                        <paragraph>In a study of healthy volunteers, chloroquine significantly reduced the bioavailability of ampicillin. Interaction of ampicillin with hydroxychloroquine cannot be ruled out. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_8">
               <id root="8cf29dd4-9195-49eb-ac39-9539536fe537"/>
               <code code="43684-0" codeSystem="2.16.840.1.113883.6.1" displayName="USE IN SPECIFIC POPULATIONS SECTION"/>
               <title>8 USE IN SPECIFIC POPULATIONS</title>
               <effectiveTime value="20241217"/>
               <component>
                  <section ID="Section_8.1">
                     <id root="ad23c4d5-ba8d-4267-8b44-8c4748338896"/>
                     <code code="42228-7" codeSystem="2.16.840.1.113883.6.1" displayName="PREGNANCY SECTION"/>
                     <title>8.1 Pregnancy</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>
                           <br/> Prolonged clinical experience over decades of use and available data from published epidemiologic and clinical studies with hydroxychloroquine sulfate use in pregnant women have not identified a drug-associated risk of major birth defects, miscarriage, or adverse maternal, or fetal outcomes <content styleCode="italics">(see Data)</content>. There are risks to the mother and fetus associated with untreated or increased disease activity from malaria, rheumatoid arthritis, and systemic lupus erythematosus in pregnancy <content styleCode="italics">(see Clinical Considerations)</content>. Animal reproduction studies were not conducted with hydroxychloroquine.<br/>
                           <br/> The estimated background risk of major birth defects and miscarriage for the indicated populations is unknown. All pregnancies have a background risk of birth defect, loss, or other adverse outcomes. In the U.S. general population, the estimated background risk of major birth defects and miscarriage in clinically recognized pregnancies is 2 to 4% and 15 to 20%, respectively.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Clinical Considerations</content>
                           <br/>
                           <br/>
                           <content styleCode="italics">Disease-Associated Maternal and/or Embryo-Fetal Risk<br/>
                           </content>
                           <content styleCode="italics">
                              <br/> Malaria:</content> Malaria during pregnancy increases the risk for adverse pregnancy outcomes, including maternal anemia, prematurity, spontaneous abortion, and stillbirth.<br/>
                           <content styleCode="italics">
                              <br/> Rheumatoid Arthritis:</content> Published data suggest that increased disease activity is associated with the risk of developing adverse pregnancy outcomes in women with rheumatoid arthritis Adverse pregnancy outcomes include preterm delivery (before 37 weeks of gestation), low birth weight (less than 2500 g) infants, and small for gestational age at birth.<br/>
                           <content styleCode="italics">
                              <br/> Systemic Lupus Erythematosus:</content> Pregnant women with systemic lupus erythematosus, especially those with increased disease activity, are at increased risk of adverse pregnancy outcomes, including spontaneous abortion, fetal death, preeclampsia, preterm birth, and intrauterine growth restriction. Passage of maternal auto-antibodies across the placenta may result in neonatal illness, including neonatal lupus and congenital heart block.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Data</content>
                           <br/>
                           <br/>
                           <content styleCode="italics">Human Data</content>
                           <br/>
                           <br/> Data from published epidemiologic and clinical studies have not established an association with hydroxychloroquine sulfate use during pregnancy and major birth defects, miscarriage, or adverse maternal or fetal outcomes. Hydroxychloroquine readily crosses the placenta with cord blood levels corresponding to maternal plasma levels. No retinal toxicity, ototoxicity, cardiotoxicity, or growth and developmental abnormalities have been observed in children who were exposed to hydroxychloroquine <content styleCode="italics">in utero</content>. Available epidemiologic and clinical studies have methodological limitations including small sample size and study design.<content styleCode="bold">
                              <content styleCode="italics"/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.2">
                     <id root="92f6203c-9954-4d75-b510-9244a0d80a21"/>
                     <code code="34079-4" codeSystem="2.16.840.1.113883.6.1" displayName="LABOR &amp; DELIVERY SECTION"/>
                     <title>8.2 Lactation</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Risk Summary</content>
                           <br/>
                           <br/> Published lactation data report that hydroxychloroquine is present in human milk at low levels. No adverse reactions have been reported in breastfed infants. No retinal toxicity, ototoxicity, cardiotoxicity, or growth and developmental abnormalities have been observed in children who were exposed to hydroxychloroquine through breastmilk. There is no information on the effect of hydroxychloroquine on milk production. The developmental and health benefits of breastfeeding should be considered along with the mother’s clinical need for hydroxychloroquine sulfate and any potential adverse effects on the breastfed child from hydroxychloroquine sulfate or from the underlying maternal condition.<content styleCode="bold">
                              <content styleCode="italics"/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.4">
                     <id root="78e82661-7de8-4a77-9666-346f289e1e7b"/>
                     <code code="34081-0" codeSystem="2.16.840.1.113883.6.1" displayName="PEDIATRIC USE SECTION"/>
                     <title>8.4 Pediatric Use</title>
                     <text>
                        <paragraph>The safety and effectiveness of hydroxychloroquine sulfate have been established in pediatric patients for the treatment of uncomplicated malaria due to <content styleCode="italics">P. falciparum, P. malariae, P. vivax</content>, and <content styleCode="italics">P. ovale, </content>as well as for the prophylaxis of malaria in geographic areas where chloroquine resistance is not reported. However, this product cannot be directly administered to pediatric patients weighing less than 31 kg because the film-coated tablets cannot be crushed or divided <content styleCode="italics">[see <linkHtml href="#Section_2.1">Dosage and Administration (2.1</linkHtml>, <linkHtml href="#Section_2.2">2.2)</linkHtml>]</content>. </paragraph>
                        <br/>
                        <paragraph>The safety and effectiveness of hydroxychloroquine sulfate have not been established in pediatric patients for the treatment of rheumatoid arthritis, chronic discoid lupus erythematosus, or systemic lupus erythematosus.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.5">
                     <id root="47b47d2b-b304-4a95-aec0-65edfbe83009"/>
                     <code code="34082-8" codeSystem="2.16.840.1.113883.6.1" displayName="GERIATRIC USE SECTION"/>
                     <title>8.5 Geriatric Use</title>
                     <text>
                        <paragraph>Clinical trials of hydroxychloroquine sulfate did not include sufficient numbers of patients 65 years of age and older to determine whether they respond differently from younger adult patients. Nevertheless, this drug is known to be substantially excreted by the kidney, and the risk of toxic reactions to this drug may be greater in patients with impaired renal function. In general, dose selection in geriatric patients should start with the lowest recommended dose, taking into consideration the greater frequency of decreased hepatic, renal or cardiac function, and of concomitant disease or other drug therapy.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_8.6">
                     <id root="8ea59d97-0765-49e4-bc62-df62c4c49d26"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>8.6 Patients with Renal or Hepatic Disease</title>
                     <text>
                        <paragraph>A reduction in the dosage of hydroxychloroquine sulfate may be necessary in patients with hepatic or renal disease.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_10">
               <id root="0d07f942-54dd-4c56-9807-7655a052c055"/>
               <code code="34088-5" codeSystem="2.16.840.1.113883.6.1" displayName="OVERDOSAGE SECTION"/>
               <title>10 OVERDOSAGE</title>
               <text>
                  <paragraph>Hydroxychloroquine sulfate overdosage symptoms have an onset within 1 to 3 hours of ingestion. The following have been reported with hydroxychloroquine sulfate overdosage: </paragraph>
                  <list listType="unordered" styleCode="disc">
                     <item>Cardiovascular toxicity, including QRS or QTc prolongation, ventricular tachycardia, ventricular fibrillation, torsade de pointes, atrioventricular block, cardiac arrest and death. </item>
                     <item>Life-threatening hypotension is common. </item>
                     <item>Severe hypokalemia secondary to an intracellular shift is common in severe toxicity. </item>
                     <item>Central nervous system (CNS) depression, seizures, visual disturbances, transient blindness, and coma may occur. </item>
                  </list>
                  <paragraph>Gastrointestinal decontamination procedures warrant consideration in patients that present within the first hour post-ingestion. If the level of consciousness rapidly deteriorates in severe poisoning, consider intubation before gastrointestinal decontamination procedures. Monitor plasma potassium levels and manage accordingly. Hemofiltration, hemodialysis, and hemoperfusion are not of benefit.</paragraph>
                  <br/>
                  <paragraph>Consider contacting a poison center (1-800-221-2222) or a medical toxicologist for overdosage management recommendations.</paragraph>
               </text>
               <effectiveTime value="20241217"/>
            </section>
         </component>
         <component>
            <section ID="Section_11">
               <id root="27fd746f-8206-4cc9-a5d5-ce4a57e72499"/>
               <code code="34089-3" codeSystem="2.16.840.1.113883.6.1" displayName="DESCRIPTION SECTION"/>
               <title>11 DESCRIPTION</title>
               <text>
                  <paragraph>Hydroxychloroquine sulfate tablets, USP are an antimalarial and antirheumatic drug, chemically described as 2-[[4-[(7-Chloro-4-quinolyl)amino]pentyl]ethylamino]ethanol sulfate (1:1) with the molecular formula C<sub>18</sub>H<sub>26</sub>ClN<sub>3</sub>O•H<sub>2</sub>SO<sub>4</sub>. The molecular weight of hydroxychloroquine sulfate is 433.95. Its structural formula is:</paragraph>
                  <paragraph>
                     <renderMultiMedia referencedObject="MM1"/>
                  </paragraph>
                  <paragraph>Hydroxychloroquine sulfate, USP is a white/off white to slight yellowish color powder, freely soluble in water and practically insoluble in ethanol (96%).</paragraph>
                  <br/>
                  <paragraph>Hydroxychloroquine sulfate tablets, USP for oral administration contain 200 mg hydroxychloroquine sulfate, USP (equivalent to 155 mg base) and the following inactive ingredients: anhydrous lactose, croscarmellose sodium, hypromellose, magnesium stearate, microcrystalline cellulose, polydextrose, polyethylene glycol, povidone, sodium lauryl sulfate, titanium dioxide and triacetin.</paragraph>
               </text>
               <effectiveTime value="20241217"/>
               <component>
                  <observationMedia ID="MM1">
                     <text>Chemical Structure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="hydroxychloro-str.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_12">
               <id root="bb5711ae-66a1-4d25-9f13-4fb5bc31b2d3"/>
               <code code="34090-1" codeSystem="2.16.840.1.113883.6.1" displayName="CLINICAL PHARMACOLOGY SECTION"/>
               <title>12 CLINICAL PHARMACOLOGY</title>
               <effectiveTime value="20241217"/>
               <component>
                  <section ID="Section_12.1">
                     <id root="55ac3335-f40e-4e97-8876-0089c84b6e56"/>
                     <code code="43679-0" codeSystem="2.16.840.1.113883.6.1" displayName="MECHANISM OF ACTION SECTION"/>
                     <title>12.1 Mechanism of Action</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Malaria</content>
                           <br/>
                           <br/> Hydroxychloroquine is a 4-aminoquinoline antimalarial <content styleCode="italics">[see <linkHtml href="#Section_12.4">Microbiology (12.4)</linkHtml>] </content>and antirheumatic agent. <content styleCode="bold">
                              <content styleCode="italics"/>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Rheumatoid Arthritis, Systemic Lupus Erythematosus and Chronic Discoid Lupus Erythematosus</content>
                           <br/>
                           <br/> The mechanisms underlying the anti-inflammatory and immunomodulatory effects of hydroxychloroquine sulfate in the treatment of rheumatoid arthritis, chronic discoid lupus erythematosus and systemic lupus erythematosus are not fully known. <content styleCode="bold">
                              <content styleCode="italics"/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.2">
                     <id root="abce22bb-b1c6-442c-aa4c-8a1b6532636b"/>
                     <code code="43681-6" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACODYNAMICS SECTION"/>
                     <title>12.2 Pharmacodynamics</title>
                     <text>
                        <paragraph>The exposure-response relationship and time course of pharmacodynamic response for the safety and effectiveness of hydroxychloroquine have not been fully characterized.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.3">
                     <id root="52fb3004-c619-4289-8f34-47139f2e9c59"/>
                     <code code="43682-4" codeSystem="2.16.840.1.113883.6.1" displayName="PHARMACOKINETICS SECTION"/>
                     <title>12.3 Pharmacokinetics</title>
                     <text>
                        <paragraph>Following oral administration, the whole blood concentration of hydroxychloroquine at steady state is dose proportional over a dose range from 200 mg daily to 400 mg daily of hydroxychloroquine sulfate  in rheumatoid arthritis and lupus patients.  </paragraph>
                        <paragraph>
                           <content styleCode="underline">Absorption</content>
                           <content styleCode="underline"> </content>
                        </paragraph>
                        <paragraph>Following a single 200 mg oral dose of hydroxychloroquine sulfate to healthy male volunteers, whole blood hydroxychloroquine C<sub>max</sub> was 129.6 ng/mL (plasma C<sub>max </sub>was 50.3 ng/mL) with T<sub>max</sub> of 3.3 hours (plasma T<sub>max</sub> 3.7 hours). Peak blood concentrations of metabolites were observed at the same time as peak levels of hydroxychloroquine. Mean absolute oral bioavailability is 79% (SD: 12%) in fasting conditions.<content styleCode="bold">
                              <content styleCode="italics"/>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>Peak blood concentrations ranged from 1161 ng/mL to 2436 ng/mL (mean 1918 ng/mL) following a single dose of 155 mg intravenous infusion and from 2290 ng/mL to 4211 ng/mL (mean 3312 ng/mL) following a single dose of 310 mg intravenous infusion in healthy subjects. Pharmacokinetic parameters were not significantly different over the therapeutic dose range of 155 mg and 310 mg, indicating linear kinetics. </paragraph>
                        <br/>
                        <paragraph>In patients with rheumatoid arthritis, there was large variability as to the fraction of the dose absorbed (i.e. 30 to 100%), and mean hydroxychloroquine levels were significantly higher in patients with less disease activity. </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Distribution</content>
                        </paragraph>
                        <br/>
                        <paragraph>Hydroxychloroquine sulfate is extensively distributed to tissues and has a large volume of distribution. Approximately 50% of hydroxychloroquine is bound to plasma proteins.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Metabolism </content>
                           </content>
                        </paragraph>
                        <paragraph>Significant levels of three metabolites, desethylhydroxychloroquine (DHCQ), desethylchloroquine (DCQ), and bidesethylhydroxychloroquine (BDCQ) were found in plasma and blood, with DHCQ being the major metabolite. <content styleCode="italics">In vitro</content>, hydroxychloroquine is metabolized mainly by CYP2C8, CYP3A4 and CYP2D6 as well as by FMO-1 and MAO-A.<content styleCode="italics"/>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">
                              <content styleCode="underline">Elimination / Excretion</content>
                           </content>
                           <content styleCode="italics">
                              <content styleCode="underline"> </content>
                           </content>
                        </paragraph>
                        <paragraph>Renal clearance in patients with rheumatoid arthritis treated with hydroxychloroquine sulfate for at least 6 months was similar to that in single dose studies in healthy volunteers, suggesting that no change in clearance occurred with chronic dosing. Renal clearance of unchanged hydroxychloroquine was approximately 16% to 30% of the dose after oral and IV administration. Results following a single oral dose of a 200 mg tablet demonstrated a half-life of hydroxychloroquine about 40 days in whole blood. Following chronic oral administration of hydroxychloroquine, the absorption half-life of hydroxychloroquine was approximately 3 to 4 hours and the terminal half-life ranged from 40 to 50 days in whole blood. The effective half-life of hydroxychloroquine is likely to be shorter and steady state is achieved by 6 weeks following 400 mg daily oral administration in rheumatoid arthritis patients.</paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="italics">Drug Interaction Studies </content>
                        </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> study suggested that hydroxychloroquine has a potential to inhibit CYP2D6, CYP3A4, P­glycoproteins (P-gp), MATE1 and MATE2-K. </paragraph>
                        <paragraph>
                           <content styleCode="italics">In vitro</content> study suggested that hydroxychloroquine has no significant potential to inhibit CYP1A2, CYP2B6, CYP2C8, CYP2C9, CYP2C19, and the main transporters OATP1B1, OATP1B3, OAT1, OAT3, OCT1, and OCT2. <content styleCode="italics">In vitro</content>, hydroxychloroquine has no significant potential to induce CYP1A2, CYP2B6 and CYP3A4. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_12.4">
                     <id root="2fb562ec-f492-4861-90cb-03d168abef2a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>12.4 Microbiology</title>
                     <text>
                        <paragraph>
                           <content styleCode="underline">Mechanism of Action in Malaria</content>
                           <br/>
                           <br/> The precise mechanism by which hydroxychloroquine exhibits activity against <content styleCode="italics">Plasmodium </content>is not known. Hydroxychloroquine is a weak base and may exert its effect by concentrating in the acid vesicles of the parasite and inhibiting polymerization of heme. It can also inhibit certain enzymes by its interaction with DNA. <content styleCode="bold">
                              <content styleCode="italics"/>
                           </content>
                        </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Antimicrobial Activity</content>
                           <br/>
                           <br/> Hydroxychloroquine is active against the erythrocytic forms of chloroquine sensitive strains of <content styleCode="italics">P. falciparum, P. malariae, P. vivax, </content>and <content styleCode="italics">P. ovale. </content>Hydroxychloroquine is not active against the gametocytes and exoerythrocytic forms including the hypnozoite liver stage forms of <content styleCode="italics">P. vivax </content>and <content styleCode="italics">P. ovale</content>. </paragraph>
                        <br/>
                        <paragraph>
                           <content styleCode="underline">Drug Resistance</content>
                           <br/>
                           <br/>
                           <content styleCode="italics">P. falciparum </content>strains exhibiting reduced susceptibility to chloroquine also show reduced susceptibility to hydroxychloroquine. Resistance of <content styleCode="italics">Plasmodium </content>parasites to chloroquine is widespread <content styleCode="italics">[see <linkHtml href="#Section_1.1">Indications and Usage (1.1)</linkHtml>]</content>. <content styleCode="bold">
                              <content styleCode="italics"/>
                           </content>
                        </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_13">
               <id root="e9354a56-dd2d-4068-9281-522293282e5f"/>
               <code code="43680-8" codeSystem="2.16.840.1.113883.6.1" displayName="NONCLINICAL TOXICOLOGY SECTION"/>
               <title>13 NONCLINICAL TOXICOLOGY</title>
               <effectiveTime value="20241217"/>
               <component>
                  <section ID="Section_13.1">
                     <id root="0fcdfe7b-3d40-4cde-a2b6-fb27c5c7bf1e"/>
                     <code code="34083-6" codeSystem="2.16.840.1.113883.6.1" displayName="CARCINOGENESIS &amp; MUTAGENESIS &amp; IMPAIRMENT OF FERTILITY SECTION"/>
                     <title>13.1 Carcinogenesis, Mutagenesis, Impairment of Fertility</title>
                     <text>
                        <paragraph>No carcinogenicity or genotoxicity studies have been conducted with hydroxychloroquine. No animal studies have been performed to evaluate the potential effects of hydroxychloroquine on reproduction or development, or to determine potential effects on fertility in males or females. </paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_15">
               <id root="422d0819-692d-4cd7-99b6-f9b451a3c359"/>
               <code code="34093-5" codeSystem="2.16.840.1.113883.6.1" displayName="REFERENCES SECTION"/>
               <title>15 REFERENCES</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">
                        <sup>1 </sup>
                     </content>Center for Disease Control and Prevention. Malaria.<br/>
                     <content styleCode="underline">https://www.cdc.gov/parasites/malaria/index.html</content>
                  </paragraph>
               </text>
               <effectiveTime value="20241217"/>
            </section>
         </component>
         <component>
            <section ID="Section_17">
               <id root="fef9d5df-59cc-4404-9306-7d7e7d34a45c"/>
               <code code="34069-5" codeSystem="2.16.840.1.113883.6.1" displayName="HOW SUPPLIED SECTION"/>
               <title>16 HOW SUPPLIED/STORAGE AND HANDLING</title>
               <effectiveTime value="20241217"/>
               <component>
                  <section ID="Section_17.1">
                     <id root="f871215d-65c7-48e1-be66-065d352e5e9a"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>16.1 How Supplied</title>
                     <text>
                        <paragraph>Hydroxychloroquine sulfate tablets, USP are available containing 200 mg of hydroxychloroquine sulfate, USP equivalent to 155 mg of base. </paragraph>
                        <br/>
                        <paragraph>The 200 mg tablets are a white, film-coated, round, biconvex, beveled edge tablet debossed with “C” on one side of the tablet and plain on the other side. They are available as follows:</paragraph>
                        <br/>
                        <paragraph>Bottles of 100 tablets                                     NDC 59651-889-01</paragraph>
                        <paragraph>Bottles of 500 tablets                                     NDC 59651-889-05</paragraph>
                        <br/>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
               <component>
                  <section ID="Section_17.2">
                     <id root="d7e7d91b-f58a-47ac-93bb-7d5308046611"/>
                     <code code="42229-5" codeSystem="2.16.840.1.113883.6.1" displayName="Spl Unclassified Section"/>
                     <title>16.2 Storage</title>
                     <text>
                        <paragraph>
                           <content styleCode="bold">Store at 20° to 25°C (68° to 77°F). [See USP Controlled Room Temperature.]</content>
                        </paragraph>
                        <paragraph>Dispense in a tight, light-resistant container as defined in the USP/NF.</paragraph>
                     </text>
                     <effectiveTime value="20241217"/>
                  </section>
               </component>
            </section>
         </component>
         <component>
            <section ID="Section_16">
               <id root="43c47453-d9bc-4011-a452-53cb5eb380ab"/>
               <code code="34076-0" codeSystem="2.16.840.1.113883.6.1" displayName="INFORMATION FOR PATIENTS SECTION"/>
               <title>17 PATIENT COUNSELING INFORMATION</title>
               <text>
                  <paragraph>
                     <content styleCode="underline">Important Administration Instructions</content>
                     <br/> Advise the patient to take hydroxychloroquine sulfate tablets with food or milk and not to crush or divide the tablet.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Cardiomyopathy and Ventricular Arrhythmias</content>
                     <br/> Inform the patient that serious cardiac effects, life-threatening and fatal cases have been reported with use of hydroxychloroquine sulfate. Advise patients to seek medical attention immediately if they experience any symptoms of heart rhythm changes including fast or irregular heartbeat, lightheadedness, dizziness, or syncope <content styleCode="italics">[see <linkHtml href="#Section_5.1">Warnings and Precautions (5.1)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Retinal Toxicity</content>
                     <br/> Inform the patient that irreversible retinal damage has been observed in some patients with the use of hydroxychloroquine sulfate. Advise patients of the importance of the ophthalmology visits for monitoring their eyes. Instruct patients to seek medical attention promptly if they experience decreased vision or decreased dark adaptation <content styleCode="italics">[see <linkHtml href="#Section_5.2">Warnings and Precautions (5.2)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Serious Skin Reactions</content>
                     <br/> Inform the patient that severe, life-threatening skin reactions have been reported with the use of hydroxychloroquine sulfate. Advise the patient to seek medical attention immediately if experiencing any of the following signs and symptoms: blisters on the skin, eyes, lips or in the mouth, itching or burning, with or without fever <content styleCode="italics">[see <linkHtml href="#Section_5.3">Warnings and Precautions (5.3)</linkHtml>].</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hepatotoxicity Associated with Porphyria Cutanea Tarda</content>
                     <br/> Inform the patient that liver toxicity has been reported in when hydroxychloroquine sulfate was used in patients with porphyria cutanea tarda. In some cases, PCT was diagnosed only after the occurrence of liver injury, when hydroxychloroquine sulfate was prescribed for an approved indication. Advise the patient to seek medical attention if experiencing fatigue, rash, nausea, dark urine, or jaundice <content styleCode="italics">[see <linkHtml href="#Section_5.5">Warnings and Precautions (5.5)</linkHtml>]</content>.</paragraph>
                  <paragraph>
                     <content styleCode="underline">Skeletal Muscle Myopathy or Neuropathy</content>
                     <br/> Inform the patient that muscle weakness and atrophy has been reported with hydroxychloroquine sulfate use. Advise patients to report to the physician symptoms of muscle weakness <content styleCode="italics">[see <linkHtml href="#Section_5.8">Warnings and Precautions (5.8)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Neuropsychiatric Reactions Including Suicidality</content>
                     <br/> Alert patients to seek medical attention immediately if they experience new or worsening depression, suicidal thoughts, or other mood changes <content styleCode="italics">[see <linkHtml href="#Section_5.9">Warnings and Precautions (5.9)</linkHtml>]</content>. </paragraph>
                  <paragraph>
                     <content styleCode="underline">Hypoglycemia</content>
                     <br/> Inform the patient that hydroxychloroquine sulfate has been associated with severe hypoglycemia. Advise the patient to monitor blood sugar levels if possible and to seek medical attention if experiencing any of the signs and symptoms of hypoglycemia such as sweating, shakiness, weakness, dizziness, tachycardia, nausea, blurred vision, confusion, fainting, or loss of consciousness <content styleCode="italics">[see <linkHtml href="#Section_5.10">Warnings and Precautions (5.10)</linkHtml>]</content>.</paragraph>
                  <paragraph>Distributed by:<br/>
                     <content styleCode="bold">Aurobindo Pharma USA, Inc.</content>
                     <br/> 279 Princeton-Hightstown Road<br/> East Windsor, NJ 08520<br/>
                     <br/> Manufactured by: <br/>
                     <content styleCode="bold">Aurobindo Pharma Limited</content>
                     <br/> Hyderabad-500 032, India<br/>
                     <br/> Revised: 12/2024</paragraph>
               </text>
               <effectiveTime value="20241217"/>
            </section>
         </component>
         <component>
            <section ID="Section_18">
               <id root="2eb1704c-b129-4c04-9c99-4cd995fdaa12"/>
               <code code="51945-4" codeSystem="2.16.840.1.113883.6.1" displayName="PACKAGE LABEL.PRINCIPAL DISPLAY PANEL"/>
               <title>PACKAGE LABEL-PRINCIPAL DISPLAY PANEL - 200 mg (100 Tablets Bottle)</title>
               <text>
                  <paragraph>
                     <content styleCode="bold">NDC 59651-889-01<br/>
                     </content>
                     <content styleCode="bold">
                        <br/> Rx only<br/>
                     </content>
                     <content styleCode="bold">
                        <br/> Hydroxychloroquine Sulfate<br/> Tablets, USP<br/> 200 mg*</content>
                  </paragraph>
                  <paragraph>
                     <content styleCode="bold">
                        <br/> KEEP OUT OF THE REACH OF CHILDREN<br/>
                        <br/> AUROBINDO            100 Tablets<br/>
                        <renderMultiMedia referencedObject="MM2"/>
                     </content>
                  </paragraph>
               </text>
               <effectiveTime value="20241217"/>
               <component>
                  <observationMedia ID="MM2">
                     <text>figure</text>
                     <value xsi:type="ED" mediaType="image/jpeg">
                        <reference value="hydroxychloro-fig1.jpg"/>
                     </value>
                  </observationMedia>
               </component>
            </section>
         </component>
      </structuredBody>
   </component>
</document>